BioNTech vs CureVac: European Patent Office declares CureVac mRNA patent valid

Published On 2025-03-28 11:41 GMT   |   Update On 2025-03-28 11:41 GMT

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac valid.

U.S.-listed shares of Germany-based CureVac rose 11.8% in extended trading.

Following the ruling, the Regional Court of Düsseldorf will decide whether the patent in its amended form has been infringed. An infringement hearing is scheduled for July 1.
The ruling represents a major milestone in the ongoing patent dispute between CureVac and BioNTech in Germany, which involves a total of six intellectual property rights related to messenger RNA (mRNA) technology.
CureVac's efforts to develop an mRNA-based COVID-19 vaccine did not come to fruition during the pandemic, whereas BioNTech and its partner Pfizer chalked up more than $40 billion in combined vaccines sales in 2021 and 2022.
In 2023, a German court invalidated a separate CureVac patent after a challenge by BioNTech. Last year, Pfizer and BioNTech won a bid to invalidate CureVac's UK COVID vaccine patents.

Read also: CureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology



Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News